USE OF COMBRETASTATIN A4 AND ITS PRODRUGS AS AN IMMUNE ENHANCING THERAPY

Details for Australian Patent Application No. 2002246756 (hide)

Owner OXIGENE, INC. BRISTOL-MYERS SQUIBB COMPANY

Inventors PERO, Ronald, W.; EDVARDSEN, Klaus; SJOGREN, Hans, Olov; Lee, Francis, Y., F.

Pub. Number AU-A-2002246756

PCT Pub. Number WO2002/058535

Priority 60/258,283 26.12.00 US

Filing date 26 December 2001

Wipo publication date 6 August 2002

Event Publications

6 February 2003 Application Open to Public Inspection

  Published as AU-A-2002246756

5 February 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002246757-Methods and compositions for treating periodontal disease

2002246755-52020, A NOVEL HUMAN MELANOMA ASSOCIATED ANTIGEN AND USES THEREFOR